Summary of disease and stage risk groups
| . | Risk . |
|---|---|
| Disease | |
| AML-favorable cytogenetics | Low |
| CLL | Low |
| CML | Low |
| Indolent B-cell NHL | Low |
| ALL | Intermediate |
| AML intermediate cytogenetics | Intermediate |
| MDS intermediate cytogenetics | Intermediate |
| Myeloproliferative neoplasms | Intermediate |
| Multiple Myeloma | Intermediate |
| Hodgkin lymphoma | Intermediate |
| DLBCL/Transformed indolent B-NHL | Intermediate |
| Mantle cell lymphoma | Intermediate |
| T-cell lymphoma, nodal | Intermediate |
| AML adverse cytogenetics | High |
| MDS adverse cytogenetics | High |
| T-cell lymphoma, extranodal | High |
| Stage | |
| 1st CR | Low |
| 2nd or subsequent CR | Low |
| 1st PR | Low |
| Untreated | Low |
| Chronic-phase CML | Low |
| 2nd or subsequent PR (if RIC) | Low |
| 2nd or subsequent PR (if MAC) | High |
| Induction failure | High |
| Active relapse | High |
| Accelerated or blast-phase CML | High |
| . | Risk . |
|---|---|
| Disease | |
| AML-favorable cytogenetics | Low |
| CLL | Low |
| CML | Low |
| Indolent B-cell NHL | Low |
| ALL | Intermediate |
| AML intermediate cytogenetics | Intermediate |
| MDS intermediate cytogenetics | Intermediate |
| Myeloproliferative neoplasms | Intermediate |
| Multiple Myeloma | Intermediate |
| Hodgkin lymphoma | Intermediate |
| DLBCL/Transformed indolent B-NHL | Intermediate |
| Mantle cell lymphoma | Intermediate |
| T-cell lymphoma, nodal | Intermediate |
| AML adverse cytogenetics | High |
| MDS adverse cytogenetics | High |
| T-cell lymphoma, extranodal | High |
| Stage | |
| 1st CR | Low |
| 2nd or subsequent CR | Low |
| 1st PR | Low |
| Untreated | Low |
| Chronic-phase CML | Low |
| 2nd or subsequent PR (if RIC) | Low |
| 2nd or subsequent PR (if MAC) | High |
| Induction failure | High |
| Active relapse | High |
| Accelerated or blast-phase CML | High |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; PR, partial remission; and RIC, reduced-intensity conditioning.